PVI
NPCE icon

Pura Vida Investments’s Neuropace NPCE Stock Holding History

Pura Vida Investments’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-229,264
Closed -$5.45M – 314
2021
Q2 		$5.45M Buy
+229,264
New +$5.32M 0.17% 109

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pura Vida Investments's NPCE Position: Q3 2021 in Review

Pura Vida Investments sold out of Neuropace (NPCE) in Q3 2021, closing a stake of 229,264 shares — an estimated $5.45M sold.

Pura Vida Investments first reported a position in NPCE in Q2 2021 and held it in 1 quarter. The position peaked at $5.45M in Q2 2021. 39 funds tracked by Wall St. Rank hold NPCE as of Q3 2021.

  • Pura Vida Investments reported no remaining Neuropace position as of Q3 2021 after selling out during the quarter.
  • Pura Vida Investments sold 229,264 Neuropace shares in Q3 2021, an estimated $5.45M.
  • Pura Vida Investments first reported a position in Neuropace in Q2 2021 and held it in 1 quarter.
  • Pura Vida Investments's Neuropace position peaked at $5.45M in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Neuropace as of Q3 2021.

Based on Pura Vida Investments's 13F filing for Q3 2021, filed 15 Nov 2021.